Kinomica
Phosphoproteomic diagnostic platform KScan for cancer treatment-response prediction, for clinicians and drug developers
Highlights
- Hiring2 open roles
- New on EvolcAdded 2026-10-28
- Remote-friendly1 of 2 open roles remote or hybrid
About Kinomica
Kinomica develops KScan, a phosphoproteomic diagnostic platform based on mass spectrometry that measures the activity of proteins rather than only their presence. The aim is to predict how a patient will respond to a range of therapies, supporting clinicians in selecting treatments.
The company's initial diagnostic tests target breast cancer, acute myeloid leukaemia and hepatocellular carcinoma. Its stated audience is clinicians and drug development, and the website describes phosphoproteomics as a way to help develop better drugs and find new drug targets.
Kinomica Limited is registered in the United Kingdom and lists its office at Biohub, Alderley Park, Macclesfield, Cheshire. It was founded in 2016 and is hiring for a Senior Bioinformatics Software Developer and an IT Lead, based in London or Alderley Park.
Product: KScan, a phosphoproteomic diagnostic platform using mass spectrometry to predict patient response to cancer treatments.
Jobs at Kinomica (2)
Kinomica is hiring for 2 roles in engineering, based in Alderley Park and London.
IT Lead
New on EvolcRemote-friendlySenior Bioinformatics Software Developer
New on EvolcRemote-friendly
Companies hiring like Kinomica
Leadership
- David Britton · Co-founderSource: company website
- John Gribben · Co-founderSource: company website
- Pedro Cutillas · Co-founderSource: company website
- Andy Thompson · Chief Product OfficerSource: company website
- Arran Dokal · Chief Technology OfficerSource: company website
- Svetlana Boumaza · Head of FinanceSource: company website
More biotech & pharma companies
Kirkstall
Organ-on-a-chip flow cell culture systems for studying drug toxicity and disease in academic and pharma labsNew on EvolcLabGenius
Machine-learning and automation platform for discovering therapeutic antibodies for biotechnology and pharmaceutical companiesNew on EvolcRemote-friendlyLario Therapeutics
Develops disease-modifying precision medicines for severe epileptic disorders and Parkinson's disease, startingYoung companyNew on EvolcLevicept
Develops a non-opioid biologic treatment for osteoarthritis pain for patients with painful joint diseaseNew on EvolcLGC Group
Reference materials, diagnostic quality controls and analytical standards for labs and life-science companiesNew on EvolcLibero Pharma
Develops transdermal naltrexone patches for patients with addiction, fibromyalgia and Crohn’s diseaseNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Bootstrap
- Cloudflare
- Google Tag Manager
- Google reCAPTCHA
- Hotjar
- WordPress
- jQuery
